Journal Papers, Abstracts, and Commentaries
| |
Role of low-frequency HIV-1 variants in failure of
nevirapine-containing antiviral therapy in women
previously exposed to single-dose nevirapine.
Boltz VF, Zheng Y,
Lockman S, et al
Proc Natl Acad Sci U S A.
2011 May 31;108(22):9202-7.
Abstract
'Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized
controlled trials:
differential impact of extended-dose nevirapine on mother-to-child transmission
and infant death
by maternal CD4 cell count.
Omer SB; for the Six Week Extended Dose Nevirapine (SWEN) Study Team.
AIDS. 2011 Feb 16
Abstract
Lack of effect from a previous single dose of nevirapine on virologic and
immunologic responses after 6 months
of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN, Hu Z, Somaroo H, Highbarger HC,
et al
Pharmacotherapy.
2011 Feb;31(2):158-63
Abstract
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in
breast milk on
early perinatal HIV-1 transmission.
Chung MH, Kiarie JN, Richardson BA, et al
J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):472-8
Abstract
|
Timing of maternal and neonatal dosing of nevirapine and the risk of
mother-to-child transmission
of HIV-1: HIVNET 024*
Chi BH, Wang L, Read JS, et al;
AIDS. 2005 Nov 4;19(16):1857-1864.
Abstract
Timing of the maternal drug dose and risk of perinatal HIV transmission in the
setting
of intrapartum and neonatal single-dose nevirapine.
Stringer JS, Sinkala M, Chapman V, et al.
AIDS. 2003 Jul 25;17(11):1659-1665.
Abstract
Comparison of Two Strategies for Administering Nevirapine
to Prevent Perinatal HIV
Transmission in High-Prevalence, Resource-Poor Settings.
Stringer JS, Sinkala M, Stout JP, et al.
J Acquir Immune Defic Syndr 2003 Apr 15;32(5):506-513
Abstract
Survival of Ugandan Infants with Subtype A and D HIV-1 Infection (HIVNET
012).
Eshleman SH, Guay LA, Fleming T, et al.
J Acquir Immune Defic Syndr 2002 Nov 1;31(3):327-30
Abstract
|
Impact
of human immunodeficiency virus type 1 (hiv-1) subtype on women
receiving
single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv
network
for prevention trials 012 study).
Eshleman SH, Becker-Pergola G, Deseyve M, et al.
J Infect Dis 2001 Oct 1;184(7):914-917
Abstract
|
Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Women
Receiving
Single-Dose Nevirapine Prophylaxis to Prevent HIV-1 Vertical Transmission
Eshleman SH, Becker-Pergola G, Deseyve M, et al
J Infect Dis 2001 Aug 13;184(7)
Abstract
|
Nevirapine: a review of its use in the prevention and treatment of
paediatric
HIV infection.
Bardsley-Elliot A, Perry CM
Paediatr Drugs 2000 Sep-Oct;2(5):373-407
Abstract |
|
Conference Reports, Abstracts, and Posters
| |
Pooled analysis of five
randomized trials of infant nevirapine prophylaxis to prevent breast-milk
HIV-1 transmission
M. Hudgens, T. Taha, S.B. Omer, et al
(6th IAS Conference)
Abstract
POSTER
4-Year Clinical and Therapeutic Consequences of
Intra-partum Single-dose Nevirapine for the Prevention of
Perinatal HIV in Women Who Subsequently Initiated a Nevirapine-based ART
G Jourdain, N Ngo-Giang-huong, S Le Coeur, et al
(16 CROI)
PDF Poster
Abstract
POSTER
Administration of Infant-only Single-dose Nevirapine
within Minutes of Birth Results in More Variable and Lower
Nevirapine Blood Concentrations
S Dross, S Rossi, I Beck, et al
(16 CROI)
PDF Poster
Abstract
POSTER
Long-term Maternal and Pediatric
Virologic Outcomes on Nevirapine-based HAART following Receipt of
Peripartum Single-dose Nevirapine or Placebo, Botswana
S Lockman, L Smeaton, A Ogwu,
et al
(16 CROI)
PDF Poster
Abstract |
|
|
Short-course Zidovudine and Lamivudine or single-dose
Nevirapine-containing PMTCT
Compromises
12-Month Response to HAART in African Women, Abidjan, Côte d’Ivoire
(2003-2006)
P Coffie, D
Ekouevi, M L Chaix. et al
(14 CROI)
Abstract
|
| |
Maternal immune response and clinical outcomes on NNRTI-based
antiretroviral therapy (ART)
following exposure to single-dose
nevirapine (NVP) for prevention of mother-to-child HIV
transmission (PMTCT)
Chi B., Sinkala M., Levy J., et al
(XVI
International AIDS Conference)
Abstract
|
| |
Infant Nevirapine Dosing for the Prevention of Mother-to-Child Transmission
in
Association with Timing of Maternal Intrapartum Nevirapine Dose: Initiatives
of
the
United States Pharmacopeia Drug Quality and Information Program (USP DQI)
Seyoum D., Primo-Carpenter J.
(3rd IAS)
Abstract
|
| |
NNRTI-resistant mutations in HIV-1 infected infants following single
dose
Nevirapine (Sd-NVP) are reduced by the addition of short course
zidovudine
and 3TC.
Gray G., McIntyre J., Hopley M., et al
(3rd IAS)
Abstract
|
| |
Frequency of nevirapine resistance (NVPR) after single dose nevirapine (sdNVP)
use to prevent HIV-1 vertical transmission: a meta-analysis
Arrivé E., Dabis F., Newell M.-L.,, et al
(3rd IAS)
Abstract
|
| |
Timing of maternal and infant nevirapine and the risk of mother-to-child
transmission
of HIV-1: HIVNET 024
Chi B.H., Wang L., Read J.S., et al
(3rd IAS)
Abstract
|
| |
6-month
immunological response with HAART containing Nevirapine in HIV infected
women post exposure to single dose of Nevirapine for PMTCT. The MTCT-Plus
Initiative
in Abidjan, Côte d’Ivoire (2003-2005).
G Bedikou,
I Viho, B Tonwe-Gold, et al
(3rd
IAS)
Abstract
|
Journal Papers, Abstracts, and Commentaries
Conference Reports, Abstracts, and Posters
Journal Papers, Abstracts, and Commentaries
|
Conference Reports, Abstracts, and Posters
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Conference Reports, Abstracts, and Posters
|
Journal Papers, Abstracts, and Commentaries
|
Conference Reports, Abstracts, and Posters
|
|
Conference Reports, Abstracts, and Posters
|
|
Nevirapine
Perinatal/Neonate Efficacy Data |
|
Monotherapy
National
Studies
Main
New/Newsworthy